within Pharmacolibrary.Drugs.ATC.L;

model L01EA01
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.98,
    Cl             = 0.00023333333333333333,
    adminDuration  = 600,
    adminMass      = 400 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.252,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.008333333333333333,
    Tlag           = 60,            
    Vdp             = 1.02,
    k12             = 49.3,
    k21             = 49.3
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01EA01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Imatinib is a tyrosine kinase inhibitor primarily used in the treatment of chronic myeloid leukemia (CML), gastrointestinal stromal tumors (GIST), and several other malignancies. Imatinib is approved for use in many countries and remains a standard therapy for CML and GIST.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult patients with chronic myeloid leukemia after oral administration. Most literature supports a two-compartment model with first-order absorption.</p><h4>References</h4><ol><li><p>Peng, B, et al., &amp; Schran, H (2005). Clinical pharmacokinetics of imatinib. <i>Clinical pharmacokinetics</i> 44(9) 879–894. DOI:<a href=&quot;https://doi.org/10.2165/00003088-200544090-00001&quot;>10.2165/00003088-200544090-00001</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16122278/&quot;>https://pubmed.ncbi.nlm.nih.gov/16122278</a></p></li><li><p>Mueller-Schoell, A, et al., &amp; Kloft, C (2021). Therapeutic drug monitoring of oral targeted antineoplastic drugs. <i>European journal of clinical pharmacology</i> 77(4) 441–464. DOI:<a href=&quot;https://doi.org/10.1007/s00228-020-03014-8&quot;>10.1007/s00228-020-03014-8</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33165648/&quot;>https://pubmed.ncbi.nlm.nih.gov/33165648</a></p></li><li><p>Lyseng-Williamson, K, &amp; Jarvis, B (2001). Imatinib. <i>Drugs</i> 61(12) 1765–1776. DOI:<a href=&quot;https://doi.org/10.2165/00003495-200161120-00007&quot;>10.2165/00003495-200161120-00007</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11693465/&quot;>https://pubmed.ncbi.nlm.nih.gov/11693465</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01EA01;
